An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease by Mularek-Kubzdela, Tatiana et al.
917w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
  E X P E R T  O P I N I O N
An expert opinion of the Polish Cardiac Society Working 
Group on Pulmonary Circulation and the Polish Society for 
Rheumatology on the diagnosis and treatment of pulmonary 
hypertension in patients with connective tissue disease
Tatiana Mularek-Kubzdela1, Michał Ciurzyński2,   Otylia Kowal-Bielecka3,  Jarosław D Kasprzak4,  Grzegorz Kopeć5, 
Katarzyna Mizia-Stec6, Ewa Mroczek7 , Ewa Lewicka8, Ilona Skoczylas9, Marek Grabka10, Michał Furdal11,  
Michał Florczyk12, Marek Brzosko13, Bogdan Batko14 , Hanna Przepiera-Będzak13, Włodzimierz Samborski15,  
Eugeniusz J Kucharz16
Reviewers: Adam Torbicki17, Piotr Wiland18
1Department of Cardiology, Karol Marcinkowski Medical University, Poznań, Poland
2Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warszawa, Poland
3Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Białystok, Poland
4Department of Cardiology, Medical University of Lodz, Bieganski Regional Specialist Hospital, Łódź, Poland 
5Pulmonary Circulation Center, Department of Cardiovascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital in Krakow, Kraków, Poland
6Department of Cardiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland
7Cardiology Department, Regional Hospital in Wrocław, Research and Development Center, Wrocław, Poland
8Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland
93rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
101st Department of Cardiology Silesian University of Medicine Katowice, Katowice, Poland
11Cardiology Department, Centre for Heart Diseases, 4th Military Hospital, Wrocław, Poland
12Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Center Otwock, Otwock, Poland
13Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology, Pomeranian Medical University, Szczecin, Poland
14Department of Rheumatology and Immunology, A.F. Modrzewski University, Kraków, Poland
15Department of Rheumatology, Rehabilitation and Internal Medicine, Karol Marcinkowski Medical University, Poznań, Poland
16Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland
17Centre of Postgraduate Medical Education, School of Medical Science, Otwock, Poland
18Department and Clinic of Rheumatology and Internal Diseases, Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland 
A B S T R A C T
Systemic connective tissue diseases (CTDs) comprise a large group of autoimmune diseases and are 
characterized by the involvement of multiple systems and organs. Pulmonary hypertension (PH) of var-
ious etiologies may develop in the course of CTD, including pulmonary arterial hypertension (PAH), PH 
secondary to the lung disease, postcapillary PH in the course of left heart disease, and chronic thrombo-
embolic pulmonary hypertension (CTEPH). In addition, the different forms of PH may coexist with each 
other. Among patients with CTD, PAH occurs most commonly in those with systemic sclerosis, where it 
affects approximately 8%–12% of patients. The prognosis in patients with untreated PAH is very poor. It is 
particularly important to identify the high-risk CTD-PAH population and to perform efficient and accurate 
diagnostics so that targeted therapy can be introduced. Echocardiography is used to screen for PH, but 
clinical and echocardiographic suspicion of PH always requires confirmation by right heart catheterization. 
Confirmation of PAH enables the initiation of life-prolonging pharmacological treatment in this group 
of patients, which should be administered in referral centers. Drugs available for pharmacological man-
agement include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclins.
Key words: pulmonary hypertension, connective tissue disease, autoimmune disease, systemic sclerosis, 
systemic lupus erythematosus
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IntroduCtIon 
Pulmonary hypertension (PH) is a clinical complication 
of systemic connective tissue diseases (CTDs), and its 
occurrence has a significant, negative prognostic value. 
The etiology of PH in patients with CTD is heterogeneous 
and includes: pulmonary arterial hypertension (CTD-
PAH); pulmonary veno-occlusive disease (PVOD; a rare, 
fatal form of PAH caused by progressive blockage of the 
capillaries and small pulmonary veins); PH secondary to 
lung disease (primary cause: pulmonary fibrosis) and/or 
hypoxemia; postcapillary PH in the setting of cardiac dis-
ease (left ventricular systolic/diastolic dysfunction); and 
chronic thromboembolic PH (CTEPH) associated with 
hypercoagulability, e.g., antiphospholipid syndrome, or 
resulting from a history of pulmonary thromboembolic 
incidents. Furthermore, more than one etiologic factor 
may be important in the pathogenesis of CTD-PH, and 
the importance of individual etiologic factors may change 
during the course of the disease. 
Given the potential for targeted therapy in PAH, it is 
particularly important to identify the high-risk CTD-PAH 
population and to initiate treatment early. Mounting 
scientific evidence confirms that early implementation 
of targeted treatment significantly prolongs life in this 
group of patients. The tremendous variability of CTD is 
associated with different prevalences of PAH in different 
types of CTD. PAH is a relatively common complication of 
systemic sclerosis (SSc); it affects 8%–12% of SSc patients 
and is associated with approximately 30% of deaths in this 
population. In contrast, it is less common in patients with 
mixed connective tissue disease (MCTD) and systemic lupus 
erythematosus (SLE) [1].
Dyspnea, which is a key symptom of PAH in patients 
with CTD, can have a variety of causes, so early diagnosis 
of CTD-PAH presents diagnostic difficulties. Screening for 
CTD-PAH should therefore be carried out regardless of 
symptomatology — it requires an active, interdisciplinary 
approach with an emphasis on cooperation between rheu-
matologists, cardiologists, radiologists, and pulmonologists 
managing patients with CTD [2, 3]. 
The development of a common scheme of regular 
screening for PAH in patients with CTD which could be 
implemented in Poland is of considerable practical im-
portance, especially considering that the percentage of 
patients with CTD-PAH is lower in Poland than in other 
countries. This observation suggests lower recognition of 
CTD-PAH and thus lower availability of treatment which 
could improve quality and length of life in this group 
of patients.
CharaCterIstICs of the most Common 
ConneCtIve tIssue dIseases 
The term CTD encompasses a large group of diseases 
characterized by the involvement of multiple systems 
and organs and assumed to be of autoimmune nature. 
The following diseases or subgroups of diseases belong 
to the CTD group: rheumatoid arthritis, systemic lupus 
erythematosus, systemic vasculitides, systemic sclerosis, 
inflammatory myopathies, Sjögren’s syndrome, juvenile 
idiopathic arthritis, and mixed connective tissue disease. 
In some cases, overlap syndromes are diagnosed in which 
symptoms and lesions of two CTDs coexist. The onset of 
symptoms and lesions indicative of CTD but in a type and 
degree that does not allow the diagnosis of a specific CTD 
may be the basis for the diagnosis of undifferentiated CTD. 
Diagnosis of CTD is difficult, primarily because of the 
varied clinical presentation and lack of pathognomonic 
indicators. One problem is overdiagnosis and, above all, 
misdiagnosis of these conditions based on autoantibodies 
alone which is, unfortunately, a common medical error. 
Classification criteria are helpful in the diagnosis of CTD. 
They are not diagnostic criteria and are therefore only used 
as an aid in the diagnostic process. 
Rheumatoid arthritis (RA) is a CTD characterized by mul-
ti-joint inflammation which primarily affects small joints, 
often occurs symmetrically, and leads to joint destruction, 
deformity, and synostosis, and thus results in disability. 
Arthritis is accompanied by changes in the tendon sheaths 
and synovial bursae, extra-articular changes (interstitial 
lung disease, pleural and pericardial effusions, and rheu-
matoid nodules in internal organs, e.g., in the lungs), and 
systemic symptoms (low-grade fever, fatigue, and lym-
phadenopathy). Serum from patients contains rheumatoid 
factor (an autoantibody directed against the Fc fragment 
of human immunoglobulin class G), which usually belongs 
to the immunoglobulin class M and less frequently to the 
immunoglobulin class G or A, anti-citrullinated protein an-
tibodies, and, of less diagnostic significance, antibodies 
against carbonylated proteins [4]. 
Systemic lupus erythematosus is a chronic autoimmune 
disease that can affect virtually all systems and organs, 
with a progressive course consisting of exacerbations and 
remissions. Numerous autoantibodies are present in the 
serum of patients, including antinuclear antibodies with 
different types of fluorescence (homogeneous, membrane, 
and patchy). Antibodies against native (double-stranded) 
DNA and anti-Sm antibodies have significant specificity. 
A decrease in the C3 and C4 complement components is 
also observed, which is helpful in assessing disease activity. 
The occurrence of anti-RNP antibodies is associated with 
the risk of developing myositis [5]. 
Systemic vasculitides are a large group of diseases with 
a common feature of inflammation in the vessel wall. CTDs 
include vasculitis with a suggested autoimmune cause, 
and may accompany other CTDs (e.g., SLE, RA). A distinc-
tion is made between the inflammation of large vessels 
(Takayasu’s arteritis, giant cell arteritis), inflammation of me-
dium arteries (polyarteritis nodosa, Kawasaki disease), small 
vessel antineutrophil cytoplasmic antibody-associated vas-
culitis (granulomatosis with polyangiitis, formerly known 
as Wegener’s granulomatosis, microscopic polyangiitis, 
eosinophilic granulomatosis with polyangiitis or Churg-
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Strauss syndrome), small-vessel vasculitis associated with 
immune complexes (a disease associated with antibodies 
to the basement membrane of the glomeruli — Good-
pasture’s syndrome; vasculitis with cryoglobulinemia; IgA 
vasculitis — Henoch-Schönlein purpura; urticarial vasculitis 
with hypocomplementemia), vasculitis of different size 
of the vessels (Behçet’s disease, Cogan’s syndrome), and 
vasculitis limited to one organ (cutaneous small-vessel 
vasculitis, primary angiitis of the central nervous system).
Granulomatosis with polyangiitis, formerly known as 
Wegener’s granulomatosis, is characterized by necrotiz-
ing granulomatous inflammation in the upper and lower 
respiratory tract, kidneys, skin, and heart, as well as other 
organs. It is a serious progressive disease. Patients are found 
to have anti-neutrophil cytoplasmic antibodies (ANCA) 
with cytoplasmic granular fluorescence (cANCA), which are 
directed against proteinase 3 and may have pathogenetic 
significance. 
Perinuclear anti-neutrophil cytoplasmic antibodies 
(pANCA) are most commonly found in patients with mi-
croscopic polyangiitis (kidney, lung, skin, and peripheral 
nerve involvement). The pANCA antibodies are directed 
against myeloperoxidase. 
Eosinophilic granulomatosis with polyangiitis, for-
merly known as Churg-Strauss syndrome, is a generalized 
necrotizing vasculitis with abundant tissue infiltrates 
composed of eosinophils, and eosinophilia is found in 
peripheral blood. Vasculitis accompanies asthma and nasal 
polyps. Eosinophilia, pANCA antibodies, asthma, lung infil-
trates (found with imagining techniques), and peripheral 
polyneuropathy are important in the diagnosis [6]. 
Systemic sclerosis (which should not be referred to as 
scleroderma because the disease does not only affect the 
skin) is a severe disease characterized by vascular changes, 
autoantibodies, and progressive fibrosis of the skin and 
internal organs. SSc should be distinguished from localized 
scleroderma, which is a separate dermatologic disease. SSc 
has several forms. Diffuse SSc (symmetrical, rapidly progres-
sive cutaneous lesions involving the face, proximal parts 
of limbs, and trunk developing together with involvement 
of internal organs) and limited SSc (not to be confused 
with localized SSc) in which skin lesions which precede 
internal organ manifestations and involve the face and 
distal parts of limbs are most commonly found. Almost all 
patients show Raynaud’s phenomenon, which may precede 
the onset of other symptoms. Patients have antinuclear 
antibodies against topoisomerase I (Scl-70 — more often 
in diffuse form), anti-centromere antibodies (ACA — more 
often in limited form), and other antibodies. PH is more 
common in the limited form of the disease [7]. 
Inflammatory myopathies are a group of diseases 
that include polymyositis, dermatomyositis, necrotizing 
autoimmune myositis, and inclusion body myositis. It is 
believed that the diseases are autoimmune in nature. They 
are characterized by muscle weakness and other changes, 
including frequent involvement of the lungs. Patients 
have multiple types of antibodies, and some patients do 
not have detectable autoantibodies. Histopathological 
examination of a muscle biopsy may be crucial for the 
diagnosis [8]. 
Antiphospholipid syndrome, known as Hughes 
syndrome, is a disease associated with autoantibodies 
to protein-phospholipid complexes causing venous 
thrombosis, arterial thrombosis, and pregnancy-related 
complications. Antiphospholipid syndrome can be primary 
or secondary, i.e., associated with another CTD – most com-
monly SLE. Thrombosis, pregnancy-related complications, 
anti-cardiolipin antibodies, anti-lipoprotein antibodies, and 
lupus anticoagulants are important in the diagnosis. Clin-
ical manifestation of the antiphospholipid syndrome can 
be very variable and the course very severe [9]. 
Sjögren’s syndrome (SS) is an autoimmune disease in 
which the glands of external secretion, such as the eye, 
mouth, and other parts of the gastrointestinal tract, be-
come inflamed. SS may precede the development of lym-
phomas. The disease may be primary, or it may accompany 
other CTDs. SSA (Ro), SSB (La), Ro-52, as well as antinuclear 
antibodies and RF are found in the patients [10]. 
Mixed connective tissue disease, although includes 
symptoms typical of other CTDs, is not an overlap syn-
drome but a separate disease entity [11].
In summary, CTDs are systemic autoimmune diseases, 
which distinguishes them from organ-directed autoim-
mune diseases (e.g., Hashimoto’s thyroiditis). Most patients 
have autoantibodies that are not themselves diagnostic. 
The organ lesions are highly variable and often involve 
the respiratory and cardiovascular systems, with vascu-
litis being common. All diseases also lead to increased 
cardiovascular mortality, in part due to accelerated ath-
erosclerosis [12]. 
Section summary
•	 The term CTDs defines a large group of diseases that 
are autoimmune in nature and characterized by the 
involvement of multiple organs and systems.
•	 CTDs are characterized by cardiovascular and respira-
tory involvement.
•	 CTDs lead to increased cardiovascular mortality and 
accelerated atherosclerosis. 
defInItIon, ClassIfICatIon, and 
epIdemIology of pulmonary 
hypertensIon
PH is diagnosed when the mean pulmonary artery pressure 
(mPAP) measured at rest during cardiac catheterization is 
≥25 mm Hg [13]; however, a recent expert opinion pro-
posed that PH should be diagnosed when mPAP >20 mm 
Hg [14]. Precapillary PH, isolated postcapillary PH, and com-
bined postcapillary and precapillary PH are distinguished 
through consideration of the hemodynamic findings, 
including pulmonary artery wedge pressure (PAWP) and 
pulmonary vascular resistance (PVR) (precapillary PH: 
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PAWP ≤15 mm Hg and PVR ≥3 Wood Units [WU]; isolated 
postcapillary PH: PAWP >15 mm Hg and PVR <3 WU, and 
combined postcapillary and precapillary PH: PAWP >15 mm 
Hg and PVR ≥3 WU). Based on etiology, pathophysiology, 
clinical presentation, and treatment strategy, PH cases are 
classified into one of the five groups shown in Table 1 [14].
PH from different clinical groups is possible in patients 
with CTD. For example, in a group of patients with SSc of 
≥3 years of duration and a diffusing capacity for carbon 
monoxide (DLCO) <60% of normal value, PH was found in 
31% of patients, of whom 60% had PAH, 27% had PH due to 
lung disease, and 21% had PH due to left heart disease [15].
Early recognition of PAH in patients is particularly 
important because of the potential for targeted therapy. 
It is a clinical condition characterized by the presence of 
precapillary PH that is not the result of lung disease, CTEPH, 
or other intermittent causes of precapillary PH (clinical 
classification group 5). PAH includes a variety of forms 
with similar clinical presentation (Table 1, Group 1 PH) and 
similar pathomorphological changes in the pulmonary 
microcirculation [13].
In the group of patients with PAH (mPAP ≥25 mm Hg) 
in Poland (n = 970), idiopathic or inherited PAH (48%), PAH 
associated with congenital heart disease (37%), and PAH as-
sociated with CTDs (CTD-PAH; 14%) were most commonly 
diagnosed [16–18]. Patients with CTD accounted for 30% 
of all patients with PAH in the Scottish registry, 25% of all 
in the US registry, and 15% of all in the French registry [19]. 
SSc is the most common systemic CTD in patients with 
PAH. Among patients with CTD-PAH in Poland, the most 
common diagnoses are SSc (48%), MCTD (17%), RA (11%), 
and SLE (10%) [16]. The incidence of PAH in patients with 
SSc in registries from various countries was estimated be-
tween 2.9% and 19% [20, 21]. The risk of developing PAH in 
these patients increases with disease duration. In a 15-year 
follow-up, PAH was diagnosed in 17% of patients with the 
limited form of SSc and in 10% with the diffuse form of SSc 
[21, 22]. The incidence of PAH was not assessed in Polish SSc 
patients. However, taking the number of patients diagnosed 
with SSc-PAH and the number of patients with SSc (accord-
ing to various sources from nearly 4000 to 10000) into ac-
count, it can be estimated that PAH is diagnosed in no more 
than 1.6% of patients with SSc [23, 24]. This probably reflects 
inadequate screening for PAH in Polish patients with SSc.
The prognosis of SSc-PAH is poor and depends on 
the functional class at the time of diagnosis. In a French 
registry in which 72% of patients were diagnosed with 
World Health Organization (WHO) functional class III or IV, 
survival at 1, 3, and 5 years of follow-up was 87%, 55%, and 
35%, respectively [25]. In contrast, in the PHAROS registry, 
in which the majority (59%) of patients had a diagnosis of 
PAH with WHO functional class I or II, the survival rates were 
95%, 75%, and 63%, respectively [26].
Section summary
•	 CTD is the third most common cause of PAH in Poland. 
Patients with SSc are at the greatest risk of develop-
ing PAH.
•	 The prevalence of PAH in patients with SSc in Poland 
is lower than in Western European countries; there-
fore, systematic screening of this group of patients 
is necessary.
•	 The prognosis of patients with PAH associated with SSc 
is poor but improves with early diagnosis.
table 1. Clinical classification of pulmonary hypertension
1. pulmonary arterial hypertension (pah)
1.1. Idiopathic PAH
1.2. Heritable PAH
1.3. PAH induced by drugs or toxins
1.4. PAH associated with:
 1.4.1. Connective tissue diseases
 1.4.2. HIV infection
 1.4.3. Portal hypertension
 1.4.4. Congenital heart defects
 1.4.5. Schistosomiasis
 1.5. PAH with good long-term response to calcium antagonist therapy
 1.6. PAH with features of venous or capillary involvement (pulmonary 
veno-occlusive disease/PCH)
 1.7. Persistent PH of the newborn
2. pulmonary hypertension due to left heart disease
2.1. Left ventricular systolic dysfunction
2.2. Left ventricular diastolic dysfunction
2.3. Valvular defects
2.4. Congenital/acquired cardiovascular disease leading  
to postcapillary PH
3. pulmonary hypertension in the course of lung disease and/or 
hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other lung diseases with mixed restrictive and obstructive changes
3.4. Hypoxia without lung disease
3.5. Lung malformations
4. Chronic thromboembolic pulmonary hypertension and other 
pulmonary artery stenoses
4.1. Chronic thromboembolic pulmonary hypertension
4.2. Other pulmonary artery obstructions
 4.2.1 Sarcoma or angiosarcoma
 4.2.2 Other malignancies: kidney cancer, uterine cancer, testicular 
germ cell tumors, other cancers
 4.2.3 Non-malignant neoplasms: uterine fibroids
 4.2.4 Arteritis without connective tissue disease
 4.2.5 Congenital pulmonary artery stenosis
 4.2.6 Parasitic diseases: Hydatidosis
5. pulmonary hypertension with unexplained and/or multifactorial 
pathomechanism
5.1. Hematopoietic system diseases: chronic hemolytic anemia, prolife-
rative bone marrow diseases
5.2. Systemic diseases and metabolic disorders: pulmonary histiocy-
tosis, Gaucher disease, glycogen storage diseases, neurofibromatosis, 
sarcoidosis
5.3 Others: chronic kidney disease (whether treated with dialysis or not), 
fibrosing mediastinitis
5.4. Complex congenital heart defects
Abbreviations: HIV, human immunodeficiency virus; PAH, pulmonary arterial hyper-
tension; PCH, pulmonary capillary hemangiomatosis.
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the role of the rheumatologIst  
In the dIagnosIs of pulmonary 
arterIal hypertensIon
PH can develop in the course of most CTDs but is by far 
the most common in SSc and SSc-related diseases such as 
MCTD and some forms of myositis [27]. The most common 
form is PAH, which affects approximately 8%–15% of SSc 
patients [27, 28]. The multi-organ nature of CTDs also in-
creases susceptibility to other forms of PH. Thromboembol-
ic PH may occur (e.g., with the antiphospholipid syndrome), 
as can PH resulting from pulmonary veno-occlusive disease 
seen in SSc. Mixed forms of PH are also possible, e.g., the 
coexistence of PAH with PH in patients with interstitial 
lung disease or heart disease [27]. Table 2 summarized the 
prevalence of PH in patients with various CTDs. It is worth 
noting that several studies provided different results due 
to various methodologies of PH detection, criteria of CTDs, 
and different populations of investigated patients. 
PH is always associated with a worse prognosis, includ-
ing a higher risk of death. The prognosis of patients with 
PAH in CTD depends on the underlying disease, with the 
highest risk of death found in patients with SSc [15, 27]. 
The analysis of the American REVEAL registry (the Registry 
to Evaluate Early and Long-term Pulmonary Arterial Hy-
pertension Disease Management) showed that one-year 
survival in patients with idiopathic PAH was 93% compared 
to 86% in patients with PAH in the course of CTD, including 
82% in SSc patients with PAH, 88% in MCTD patients with 
PAH, 94% in SLE patients with PAH, and 96% in RA patients 
with PAH [29]. 
Due to its relatively frequent occurrence and progres-
sive course, PAH is now the second most common cause 
of death in SSc patients, next to interstitial lung disease 
[30]. The prognosis of PAH depends on its clinical stage. 
Early diagnosis of PAH is therefore crucial to improve 
prognosis, especially since drugs are available that can 
slow disease progression.
Diagnosis of PAH in the early stages is not easy because 
of the low sensitivity and specificity of clinical signs. In the 
early stages of the disease, the patient may not feel any 
discomfort, especially considering the fact that the physical 
function of patients is often limited due to the musculo-
skeletal complaints that are very common in CTD. Secondly, 
the patient’s adaptation to the chronically developing dis-
ease process means that symptoms are not felt until very 
advanced stages. Thirdly, decreased exercise tolerance in 
the absence of very discrete PH physical symptoms may 
be overlooked or misinterpreted as an expression of CTD 
or age, especially in patients over 50 years old. Therefore, 
early diagnosis of PH requires vigilance on the part of phy-
sicians caring for patients with CTD and regular evaluation 
of these patients for PH.
In clinical practice, it may be helpful to know the profile 
of patients at higher risk of developing PH. As mentioned 
above, PAH is particularly common in SSc and CTD patients 
with similar clinical presentations (MCTD, overlap syn-
dromes with SSc). Risk factors for PAH in patients with SSc 
are listed in Table 3. It is worth noting that PAH develops 
relatively frequently in patients with skin lesions limited to 
the distal parts of the extremities, often only the fingers (so-
called sclerodactyly or simply swollen fingers), which can 
easily be overlooked by both the patient and the medical 
table 2. Prevalence of pulmonary hypertension in patients with systemic connective tissue diseases (from various sources)
disorder prevalence Comments
Rheumatoid arthritis <1% Common association with chronic respiratory symptoms
Systemic lupus 
erythematosus
1%–3% Unfavorable prognosis is associated with WHO Functional class III/IV, higher mean pulmona-
ry arterial pressure, lower 6 minutes walking distance, and higher N-terminal proBNP
Systemic vasculitides 1%–3%; higher rate in patients with 
antineutrophil cytoplasmic antibody
-associated vasculitis (about 10%)
In most cases PH is caused by pulmonary thromboembolism, PAH is relatively rare;  
renal and skin involvement is commonly associated with PH
Systemic sclerosis PAH 8–15%




5%–50% High prevalence in patients with interstitial lung disease and anti-aminoacyl-transfer RNA 
synthetases autoantibodies. Higher prevalence in Asian population
Antiphospholipid 
syndrome
5%–15% The majority of patients develop chronic thromboembolic pulmonary hypertension; some 
suffer from PH after acute pulmonary thromboembolism. High titer of antiphospholipid 
antibodies is considered as a risk factor
Sjögren’s syndrome 5%–20% In most cases, PH is related to pulmonary involvements in patients  
with primary Sjögren’s syndrome. PAH is relatively rare. Prevalence of PH is significantly 
common in female Asian patients with non-specific intestinal pneumonia.  
Early Raynaud’s phenomenon is a risk factor for PH
Mixed connective 
tissue disease
2–8% Occurrence of significant symptoms and signs akin to systemic sclerosis are associated  
with a higher prevalence of PH
Abbreviations: PH, pulmonary hypertension; WHO, World Health Organization. Other — see Table 1
table 3. Risk factors for pulmonary arterial hypertension in patients 
with systemic sclerosis
risk factors for pulmonary arterial hypertension in patients with 
systemic sclerosis
A limited form of systemic sclerosis*
Presence of anti-centromere antibodies 
Presence of telangiectasia
Longer duration of illness
Older age
Elevated uric acid levels
*The limited form of systemic sclerosis is characterized by the involvement of the 
skin only in the distal parts of the body (below the line of elbows and knees; the 
face is usually also involved)
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staff. Sometimes exertional dyspnea is the reason for seek-
ing help and making the diagnosis of CTD. Unfortunately, at 
this stage, lung disease (PAH and/or interstitial lung disease) 
is usually already very advanced. Therefore, all patients with 
Raynaud’s syndrome (present in almost all SSc patients from 
the onset of the disease), SSc-specific antibodies (especially 
ACA) and/or SSc-specific microangiopathy present, and 
even discrete skin lesions should be evaluated for PH. Re-
garding telangiectasias, it is worth remembering that those 
typical of SSc have a regular shape (round or oval) and are 
usually observed on the face, hands, and/or neckline. 
International guidelines recommend regular screening 
of patients with SSc and SSc-associated diseases for PH [21, 
31–33]. Echocardiography plays a major role in screening. 
The importance of this test in the diagnosis of PH in patients 
with CTD is discussed in a separate section. Unfortunately, 
in practice, it is not always possible to evaluate all patients 
annually with echocardiography. The test can also produce 
false-negative results, especially in patients with early PH 
without tricuspid regurgitation, which prevents the esti-
mation of right heart pressures.
The inclusion of other clinical, functional, and biochem-
ical parameters in screening may improve the detection 
of PAH in patients with CTD [21, 28, 31–33]. The DETECT 
algorithm, based on the analysis of the aforementioned 
study, is designed to determine the risk of PAH in patients 
with SSc [15]. As shown in Figure 1, the DETECT algorithm 
includes two steps: the first is to assess the need for echo 
and the second is to qualify for right heart catheterization. 
In the first stage, the forced vital capacity/diffusion capac-
ity of the lung for carbon monoxide ratio, the presence 
of telangiectasias (current or past), the presence of ACA 
antibodies, serum NT-proBNP and uric acid levels, and the 
right axis deviation on the ECG recording are evaluated. 
Individual parameters are assigned points based on the 
developed nomograms. A total score greater than 300 in-
dicates the need for echocardiography. The second stage 
considers the scores from the first stage, the tricuspid re-
gurgitation velocity, and the right atrium area. As in stage 
one, all parameters are prescribed scores based on nomo-
grams. A second stage total score greater than 35 indicates 
the need for right heart catheterization.
The DETECT algorithm proved to be more sensitive 
compared with the echo study (evaluation according 
to European Society of Cardiology [ESC], and European 
Respiratory Society [ERS] guidelines): the sensitivity of 
the DETECT algorithm was 96% compared with 71% for 
the echo study. Similarly, the negative predictive value of 
the DETECT algorithm was higher (98%) compared with 
the echo study (89%). The DETECT calculator is available 
online on the website and as an app.
According to recent recommendations, patients with 
SSc and other CTDs with features of SSc (sclerodactyly, 
characteristic microangiopathy, and/or antibodies) and 
DLCO values <80% of normal values should undergo 
annual screening for PH [32]. As illustrated in Figure 2, pa-
tients with suspected PH based on the DETECT algorithm 
(DETECT score >35 points) or echocardiography with forced 
vital capacity (FVC) / DLCO >1.6 and/or NT-proBNP levels 
exceeding the upper limit of normal 2 times (after exclud-
ing other causes) should be referred to centers specializing 
in diagnosing PH for right heart catheterization.
Clinical studies suggest that the use of PH screening 
programs in practice enables earlier diagnosis and treat-
ment of PAH, which in turn improves prognosis in this 
group of patients [21, 26, 32–33]. 
Section summary 
•	 Risk factors for PAH in patients with SSc include limited 
SSc, presence of ACA antibodies, presence of telan-
giectasias, longer duration of disease, older age, and 
elevated uric acid levels.
— Pulmonary function tests (FVC/DLCO ratio)
— Telangiectasias (present or past)
— Anti-centromere antibodies (ACA)
— Serum NT-proBNP concentration
— Serum uric acid concentration
— Right axis deviation on ECG
— Scoring from Stage 1
— Right atrial area (RAA)
— Tricuspid regurgitation velocity (TRV)
Right heart catheterization 
Total points > 300
Total points > 35
Stage 1:




figure 1. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis. Based on [15]
Abbreviations: DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity
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•	 Screening for PH should be based on a comprehensive 
assessment that includes risk factors, clinical presenta-
tion, and additional test results, including pulmonary 
function tests (FVC, DLCO), NT-proBNP/BNP, and uric 
acid levels.
•	 The DETECT algorithm facilitates the selection of pa-
tients who require echocardiography and right heart 
catheterization and increases the sensitivity of diag-
nosing PAH in SSc patients.
•	 Patients with PH in the course of CTD should be cared 
for by a multi-specialist team consisting of a rheuma-
tologist and a cardiologist.
pulmonary arterIal hypertensIon 
In ConneCtIve tIssue dIseases: the 
CardIologIst’s role In dIagnosIs 
The primary goals of cardiological diagnosis in a patient 
with suspected PAH are to determine the indications for 
invasive diagnosis (right heart catheterization), to establish 
the diagnosis of PH and its type, and to determine the pos-
sibility of including PAH-targeted therapy, which depends 
on confirmation of PAH or CTEPH.
An established diagnosis of SSc or SSc-related diseases 
is a strong risk factor for the occurrence of PAH with an 
extremely unfavorable prognosis and increases the risk 
of deep vein thrombosis severalfold, which can lead to 
CTEPH [34]. The coexistence of interstitial lung disease in 
the setting of CTD (including capillary and small pulmo-
nary vein pathology) is a problem typical for SSc, which 
may exclude patients from PAH-targeted therapies. Forced 
expiratory volume in one second (FEV1) <70% (obturation) 
and FVC <70% (restriction) are taken as criteria supporting 
a predominant role of pulmonary etiology.
The diagnosis of PAH in a patient with CTD may follow 
two diagnostic pathways. The first pathway applies to the 
evaluation of a patient with symptoms suggestive of PAH 
(which are difficult to distinguish from symptoms of pulmo-
nary complications of SSc). The second pathway applies to 
the evaluation of a patient without specific symptoms un-
dergoing annual screening for CTD from the SSc spectrum.
The evaluation of a symptomatic patient with CTD does 
not differ from the general criteria used in PAH. Typical 
symptoms warrant urgent echocardiography with the 
assessment of the likelihood of PH and its clinical impli-
cations. An asymptomatic patient should be referred to 
a cardiologist for echocardiography as part of a screening 
program either once per year (if an echocardiographic 
screening strategy is chosen and echocardiography is 
readily available in a center specializing in the assessment 
of right-sided cardiac circulation), or in the event of a pos-
itive screening test if another screening strategy is used 
(e.g., FVC/DLCO ratio >1.6 and/or NT-proBNP concentration 
>2 times normal; DETECT algorithm with the index after 
stage I more than 300 points).
Echocardiography is the primary noninvasive method 
for determining the risk of PH. Its evaluation requires 
measurement of maximum tricuspid regurgitation veloc-
ity and phenotypic features of cardiac imaging in PH. The 
examination should be performed by a center specializing 
in the assessment of the pulmonary circulation in optimal 
technical quality, using the projections optimized for 
assessment of the right-sided cardiac cavities [35]. The 
evaluation principles are shown in Table 4.
In a symptomatic patient with CTD, a finding of interme-
diate or high probability is a relative (recommendation class 
IIa/B) or an absolute (I/C) indication, respectively, for a full 
PH evaluation in a specialized center with consideration 
of right heart catheterization. In an asymptomatic patient 
with SSc, a finding of intermediate probability is a relative 
indication for right heart catheterization (recommenda-
tion class IIa/B), whereas a high probability with any CTD 
is an absolute (I/C) indication for a full PH evaluation in 
a specialized center including right heart catheterization.
If echocardiography is used as the second stage of 
the DETECT algorithm, echocardiographic assessment 
of the maximal (end-systolic) right atrial area assessed in 
the four-chamber view and the velocity of the maximal 
tricuspid regurgitant return wave is crucial. If the threshold 
of 35 points is exceeded in the second stage of the algo-
rithm, right heart catheterization at an expert PH center 
is indicated. 
In most patients, pulmonary ventilation-perfusion scin-
tigraphy, computed tomography pulmonary angiography, 
or conventional pulmonary cineangiography during right 
heart catheterization is necessary to rule out a pulmonary 
artery thromboembolism component regardless of the 
patient’s history. High resolution computed tomography 
of the lungs aids in the differential diagnosis of uncom-
figure 2. Algorithm to detect pulmonary hypertension in patients 
with SSc/scleroderma spectrum disorders. Based on [32]
Abbreviations: ILD, interstitial lung disease. Other — see Figure 1
Patients with:
— Systemic sclerosis or diseases of the sclerosis group 
 (mixed connective tissue disease and other diseases 
 with features of systemic sclerosis: sclerodactyly, 
 microangiopathy and/or characteristic antibodies) 
 and DLCO < 80%
—  DETECT algorithm (> 35 points)
—  Echocardiography (2015 ECS/ERS guidelines)
—  Pulmonary function tests (FVC/DLCO > 1.6), 
 after exclusion of ILD
—  NT-proBNP > 2× upper limit of normal
Right heart catheterization 
Screening for pulmonary 
hypertension every year
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mon pulmonary capillary hemoangiomatosis/pulmonary 
venoocclusive disease, which require different therapeutic 
approaches. Right heart catheterization is the definitive 
diagnostic method to establish the hemodynamic indi-
ces necessary to establish the diagnosis of PAH (see the 
section on classification and criteria) and the decision 
to initiate targeted therapies. These indices include 
mPAP, PVR (using reversibility tests after administration 
of nitric oxide or prostacyclin analogs), and possibly 
the trans-pulmonary gradient. In borderline cases with 
difficult differentiation of precapillary and postcapillary 
components, additional measurement of PCWP during 
exercise or after fluid loading may be performed. Existing 
treatment recommendations have been established in 
studies of patients who meet the traditional definition of 
PH, i.e., mPAP ≥25 mm Hg.
Section summary
•	 Asymptomatic patients with CTD on the SSc spectrum 
should undergo annual screening for PH, and in Polish 
conditions, echocardiography may be the preferred, 
most universal method (recommended regardless of 
the DLCO result). In other types of CTD, echocardiog-
raphy is performed when PH is clinically suspected.
•	 The decision on whether indications warrant right heart 
catheterization to establish a conclusive diagnosis is 
made by the cardiologist, and the examination should 
be performed in expert PH centers. The DETECT algo-
rithm is useful in patient selection for right heart cath-
eterization.
•	 The final determination of the type of PH and the 
appropriateness of inclusion in a treatment program 
for patients with CTD should be undertaken in expert 
PH centers.
treatment of pulmonary arterIal 
hypertensIon
Patients with CTD who are diagnosed with PAH should be 
treated the same as all other patients with category I PH, 
according to current guidelines. This is because in most of 
the large, randomized trials conducted to register drugs for 
PAH, approximately 30% of patients were CTD patients [31, 
36]. The only difference is that high-dose calcium antago-
nists are not recommended in patients with CTD-PAH, as 
a positive response has been reported in less than 1% of 
patients [37]. Anticoagulants are also not used due to the 
unfavorable risk/benefit ratio of bleeding [38].
Treatment of PAH is always done at a referral center. 
There are currently 24 PAH treatment referral centers for 
adults and nine pediatric centers in Poland (PAH treatment 
centers in Poland: www.skp.ptkardio.pl/osrodki_dorosli, www.
skp.ptkardio.pl/osrodki-dzieci). 
General recommendations
•	 Encourage patients to engage in symptom-limited 
physical activity and supervised rehabilitation.
•	 Influenza and pneumococcal vaccinations.
•	 Iron suplementation should be considered in patients 
with iron deficiency: serum ferritin <100 μg/l, or ferritin 
between 100–299 μg/l and transferrin saturation <20%.
•	 Diuretics in patients with fluid retention.
•	 Oxygen therapy: when arterial blood oxygen partial 
pressure is <60 mm Hg or when arterial blood oxygen 
saturation is <91%, oxygen is recommended for at least 
15 hours per day.
Targeted pharmacotherapy  
(specific to pulmonary arterioles)
In the treatment of PAH, three groups of drugs are used: 
•	 Drugs that affect the endothelin pathway: endothe-
lin receptor antagonists, which include ambrisentan, 
bosentan, and macitentan
•	 Drugs that affect the nitric oxide pathway: phosphodi-
esterase-5 inhibitors, which include sildenafil, tadalafil, 
vardenafil, and guanylyl cyclase stimulators, which 
include riociguat
•	 Drugs that affect the prostacyclin pathway: prostacy-
clins, which include beraprost, epoprostenol, iloprost, 
treprostinil, and IP prostacyclin receptor agonists, which 
include selexipag
Within the National Health Fund drug program for 
the treatment of PAH in Poland, bosentan, macitentan, 
sildenafil, riociguat, epoprostenol (iv), iloprost (inhaled), 
treprostinil (sc), and selexipag can be prescribed. All these 
drugs have vasodilatory effects and lower pulmonary artery 
pressure; however, they also have antiproliferative effects 
that reduce the proliferation of endothelial cells and pul-
monary arterial smooth muscle. Parenteral prostacyclins 
have the strongest effect; in addition, they are the most 
potent endogenous inhibitors of platelet aggregation [31].
table 4. Algorithm for assessing the likelihood of pulmonary hypertension on transthoracic echocardiography according to [31]
maximum tricuspid regurgitation  
wave velocity, m/s
presence of other echocardiographic  
features of pulmonary hypertension*
echocardiographic probability  
of pulmonary hypertension
≤2.8 or not measurable No Low




*At least two features from three categories suggesting: right ventricular enlargement, increased pulmonary artery pressure or increased pulmonary vascular resistance, 
features indicative of high right atrial pressure
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The choice of initial therapy, as well as the timing of 
escalation of therapy in long-term follow-up, is based on 
an assessment of the risk of death within one year. Several 
risk stratification tools exist, including the REVEAL 2 scale 
[39], risk assessment based on the Swedish [40], French [41], 
COMPERA [42] registry, and ESC risk tables [31]. In Poland, 
the ESC risk stratification table is most commonly used 
(Table 5). The risk of death is assessed at baseline and at 
4- to 6-month intervals thereafter, and considers a dataset 
derived from clinical assessment, six-minute walking test, 
ergospirometry, biochemical markers, echocardiography, 
and right heart catheterization. Although CTD-PAH is 
a more aggressive disease than idiopathic PAH, this method 
of risk stratification has also been validated in this group 
of patients [43].
The earlier therapy is started, the better the results of 
PAH treatment. This applies to all patients with PAH, includ-
ing patients with CTD-PAH. In the French Registry, 3-year 
survival in patients with SSc was 80% when treatment 
started in NYHA class II, 72% in class III, and 30% in class IV 
[43]. There is also evidence that, in patients with CTD-PAH, 
survival is better when treatment is initiated as a result of 
screening than when diagnosis and treatment occur due 
to the severity of clinical symptoms [44].
According to the ESC and World Hypertension Forum 
recommendations, at low or intermediate risk of death, 
therapy should be initiated with two oral drugs from two 
different groups (endothelin receptor antagonist + phos-
phodiesterase-5 inhibitor) [31, 45]. The National Health 
Fund drug program does not reimburse this course of ac-
tion: the therapy has to start with one drug, but if it proves 
ineffective, another drug can be added. Expert groups 
of both societies contributing to this statement suggest 
eliminating this gap in the therapeutic program, as it does 
not comply with current ESC/ERS guidelines, while no 
longer being justified by financial reasons, as oral generic 
ET-1 receptor antagonists and PDE5i are currently availa-
ble at a low cost. When the patient is initially at high risk, 
combination therapy, including prostacyclin, is applied.
The essence of managing a patient with PAH is to main-
tain assessed parameters within a low-risk-of-death profile, 
which is synonymous with a good prognosis. If some of 
these parameters fall into the intermediate or high-risk 
profile, it means that the patient is inadequately treated 
and the therapy needs to be intensified by the addition of 
another drug, change to a more potent one, or increase 
of the dose [46].
 If triple-drug therapy is ineffective, patients should 
be referred for lung transplantation. Lung transplantation 
is not contraindicated in patients with CTD-PAH [47], 
although indications and contraindications must include 
evaluation of other organs that may be involved, particu-
larly the gastrointestinal tract (reflux disease and intestinal 
disease), heart, kidney, and skin [47]. 
Despite targeted pharmacotherapy, the prognosis of 
patients with CTD, especially those with SSc and related 
diseases, is worse than that of patients with idiopathic 
PAH [48, 49]. A 2021 meta-analysis of 12 randomized 
trials and 19 registries with at least 30-patient subgroups 
with CTD-PAH from 2000 to 2019 showed a slightly lower 
mortality rate in patients with CTD, albeit still higher than 
in other groups of patients with PAH. The 3-year survival 
was lower in patients with CTD-PAH vs all patients: 62% 
vs 72%, respectively. The 3-year survival of patients with 
CTD-PAH after 2010 was better than before 2010 at 73% 
vs 65%, respectively [50]. 
In a randomized trial involving 111 patients with SSc, 
3-month treatment with intravenous epoprostenol infusion 
improved physical performance, hemodynamic parame-
ters, and functional class [51]. Subgroup analyses of pa-
tients with CTD-PAH or SSc from randomized trials in which 
sildenafil, tadalafil, bosentan, ambrisentan, macitentan, 
subcutaneous treprostinil, riociguat, and selexipag were 
administered showed a beneficial effect of these drugs, 
table 5. Risk assessment in pulmonary arterial hypertension
prognostic value (estimated  







Clinical manifestation of right  
ventricular failure
No No Yes
Rate of progression of symptoms Absent Slow Fast
Syncope Absent Sporadic Frequent
WHO functional class I, II III IV
Six-minute walk test >440 m 165–440 m <165 m
Ergospirometry VO2 max >15 ml/min/kg  
(>65% pred.)
VE/VCO2 slope <36
VO2 max 11–15 ml/min/kg 
(35%–65% pred.)
VE/VCO2 slope 36–44.9
VO2 max <11 ml/min/kg  
(<35% pred.)
VE/VCO2 slope ≥45











no or minimal pericardial effusion
RAA >26 cm2
pericardial effusion
Hemodynamics RAP <8 mm Hg
CI ≥2.5 l/min/m2
SvO2 >65%
RAP 8–14 mm Hg
CI 2.0–2.4 l/min/m2
SvO2 60–65%
RAP >14 mm Hg
CI <2.0 l/min/m2
SvO2 <60%
Abbreviations: BNP, B-type natriuretic peptide; CI, cardiac index; CMR, cardiac magnetic resonance; NT, N-terminal; RAA, right atrial area; RAP, right atrial pressure; SVO2, veno-
us oxygen saturation; VE, minute ventilation; VCO2, carbon dioxide production; VO2, oxygen consumption; WHO, World Health Organization
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although the improvement was not always statistically sig-
nificant. Some of these studies showed that the treatment 
effect was smaller in patients with CTD-PAH than in patients 
with idiopathic PAH [52]. This could be because CTDs, which 
are systemic diseases, cause damage to multiple organs 
[27]. The small size of the CTD-PAH subgroups may also 
have had some influence on these results, hampering the 
achievement of statistically significant results. A common 
endpoint in these studies was the six-minute walking test, 
which may show worse results in patients with CTD because 
of the muscular or joint problems or fatigue associated 
with the underlying disease [27]. In contrast, since 2013, 
when the SERAPHIN, GRIPHON, and AMBITION trials were 
released, an analysis of subgroups of patients with CTD-PAH 
showed a significant reduction in the composite endpoint. 
In these studies, the endpoint included morbidity and 
mortality, and the time from study drug inclusion to the 
first incident (death, worsening, hospitalization for pros-
tacyclin inclusion, lung transplantation, or septostomy) 
was assessed. In addition, in the SERAPHIN and GRIPHON 
trials, 64% and 80%, respectively, were already receiving 
PAH-targeted therapy at baseline, so the addition of an 
investigational drug was often a combination therapy 
[53-56]. The AMBITION study additionally showed that, as 
in the overall group, in patients with CTD and in patients 
with SSc, initial treatment with tadalafil and bosentan was 
more beneficial than initial monotherapy [53]. The afore-
mentioned 2021 meta-analysis, based on five randomized 
trials evaluating time to incident mortality/morbidity, 
showed the same 36% reduction in the risk of incident 
mortality/morbidity in treated vs placebo in the whole 
group as well as the CTD-PAH subgroup [46]. 
Section summary 
•	 PAH in patients with CTD and especially in those with 
SSc has a high mortality rate.
•	 Prognosis can be improved by the earliest possi-
ble inclusion of targeted therapy, preferably based 
on screening.
•	 This treatment should be aggressive and include initial 
combination therapy.
•	 Targeted therapy given to patients with CTD-PAH 
improves the quality of life, physical function, and he-
modynamics and reduces mortality/morbidity.
does dIagnosIs of pulmonary arterIal 
hypertensIon Change the management 
of a patIent wIth ConneCtIve tIssue 
dIsease?
The causes and mechanisms of CTD development are 
unknown, so treatment is limited to immunosuppressive 
drugs and symptomatic treatment of organ lesions. The es-
sence of autoimmunization is the generation of immunity 
against one’s own antigens. In the absence of the ability 
to correct impaired immune tolerance, treatment comes 
down to reducing the overall immune response. The drugs 
used combine immunosuppressive, anti-inflammatory, and 
antiproliferative effects, and delineating these actions is 
difficult. If a patient with CTD has PAH, the following issues 
regarding the interrelationship of CTD and PAH treatment 
should be considered:
•	 Does a decrease in the overall activity of the disease pro-
cess in CTD reduce the occurrence and severity of PAH?
•	 Can drugs used in patients with CTD (e.g., symptom-
atic — affecting organ changes) exacerbate (or even 
trigger) the onset of PAH in this group of patients?
•	 Can drugs used in patients with CTD interact with the 
treatment of PAH, and thus require modification of their 
simultaneous co-administration? 
The therapeutic problems presented have no clear 
answer. 
The incidence of PAH in CTD patients has been pre-
sented in earlier sections of this paper. There is a prevailing 
belief that the development of PAH is an expression of the 
severity of the disease, but there is no clear association with 
other indicators of disease process activity. Moreover, the 
clinical presentation of CTD is highly variable. Despite the 
lack of studies, however, it is plausible that the develop-
ment of PAH shares a common pathogenesis with other 
organ lesions, and therefore, early and prolonged reduction 
in disease activity is beneficial to pulmonary circulation. 
However, detection of PAH usually occurs so late that reduc-
tion of disease activity alone is not sufficient to control PAH. 
A case of resolution of PAH and interstitial lung disease in 
an SLE patient after treatment with mycophenolate mofetil 
was described [57]. This is consistent with animal model 
studies in which the active metabolite of mycophenolate 
mofetil has been shown to inhibit pulmonary artery wall 
remodeling in rats. Similarly, intensive treatment of SLE 
with cyclophosphamide and corticosteroids may be asso-
ciated with a reduction in PAH [58]. On the other hand, it 
has been reported that PH can be associated with an ele-
vated level of mineralocorticoids and medication against 
mineralocorticoid activity is beneficial. Administration of 
glucocorticoids can exert some mineralocorticoid activity 
and such drug action should be considered. In most cases, 
anti-inflammatory and immunosuppressive action of glu-
cocorticoids predominates their mineralocorticoid activity. 
Administration of non-steroidal antirheumatic drugs 
is associated with inhibition of prostaglandin synthesis. It 
may an be additional unfavorable factor in patients with 
PH, thus should be considered in a long-term therapeu-
tic strategy.
There is no reliable evidence indicating lung injury and 
the occurrence of PAH in patients treated with immuno-
suppressive drugs. The few case reports refer to infectious 
complications that damage the lungs and may promote 
secondary development of PAH, rather than a direct effect 
of immunosuppressants causing PAH. Single case reports 
suggest that the disease-modifying drug leflunomide 
may induce PAH. Leflunomide is metabolized to teri-
flunomide, which inhibits de novo pyrimidine nucleotide 
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synthesis. Moreover, the drug inhibits the activity of cy-
clooxygenase-2 and thus the production of prostaglandin 
E2. This mechanism may be linked to the development of 
PAH [59]. Leflunomide has also been linked to the sporadic 
development of interstitial lung disease in RA patients [60]. 
Another disease-modifying drug, methotrexate, has an-
tiproliferative effects at high doses and anti-inflammatory 
effects at lower concentrations through its effects on aden-
osine metabolism. The use of methotrexate has been linked 
to pulmonary fibrosis, but most contemporary studies 
show the opposite effect — inhibition of the inflammatory 
process reduces the development of pulmonary fibrosis 
[61]. No study has confirmed the impact of methotrexate 
on the development of PAH. Methotrexate is also used in 
proliferative hematopoietic diseases, and the beneficial 
effects of methotrexate on PH have been described in 
patients with T-lymphocytic leukemia [62]. Other drugs 
known to cause PAH are not regularly administered (and 
should not be administered) in patients with CTD. 
Single case reports and uncontrolled clinical obser-
vations suggest that immunosuppressive drugs may be 
combined with drugs used to treat PAH – they seem to work 
synergistically. Adverse effects of bosentan in SSc patients 
have been described, including an increase in arthritis as 
well as an increase in methotrexate hepatotoxicity [63]. This 
is explained by the inhibitory effect of bosentan on endog-
enous glucocorticoid secretion. However, it is important to 
remember that the inflammatory process in SSc patients is 
revealed only in the early stages of the disease or in overlap 
syndromes between SSc and other CTDs.
Section summary
•	 In patients with CTD complicated by PAH, the un-
derlying disease and PAH should be treated without 
modifying therapeutic strategy. 
•	 Increasing the number of drugs used raises the risk 
of adverse interactions and requires more intensive 
therapeutic surveillance.
•	 The occurrence of PAH reduces the patient’s exercise 
tolerance, which may require lifestyle changes, avoid-
ance of respiratory infections, and changes in the 
rehabilitation used. 
summary
Various organs and systems, including the cardiovascular 
and respiratory systems, may be involved in the course 
of CTD. One of the complications of CTD that affects the 
prognosis most heavily is PH. The etiology of PH in patients 
with CTD is heterogeneous and includes PAH, PH second-
ary to interstitial lung disease, postcapillary PH secondary 
to left heart disease, and CTEPH. In addition, several PH 
mechanisms may coexist in a patient, which significantly 
complicates diagnosis and treatment. Among CTD patients, 
PAH occurs most frequently in those with SSc, in whom 
it affects approximately 8%–12% of patients. PH should 
be suspected on the basis of clinical symptoms by the 
rheumatologist or cardiologist caring for the patient. The 
symptomatic patient should be referred to a cardiology 
center for diagnosis of PH. In asymptomatic patients with 
SSc, echocardiography should be considered every year, or 
in the event of a positive screening test if another screen-
ing strategy is used (FVC/DLCO >1.6 and/or NT-proBNP 
levels > 2 times normal or DETECT algorithm with a post-
stage I score of more than 300 points). Clinical suspicion 
of PH always requires confirmation with right heart cathe-
terization, which also helps to determine the mechanism 
of PH. Patients with confirmed PAH should be referred to 
a cardiology referral center for targeted therapy. The care 
for patients with CTD requires collaboration between the 
rheumatologist treating the underlying disease and the 
cardiologist diagnosing and treating PH.
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